We found that KLF5 had lower expression in metastatic tumours versus primary tumours and normal tissue, hence potentially acting as a tumour/metastatic suppressor, whereas SP1 displayed the opposite pattern, functioning likely as a tumour/metastatic promoter (Fig. 7C). This evidence concerns the gene KLF5 and neoplasm.